ReviewSensors (Basel, Switzerland)2020
A Survey of Alzheimer's Disease Early Diagnosis Methods for Cognitive Assessment.
Review in Sensors (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Effects of virtual reality with different modalities on upper limb recovery: a systematic review and network meta-analysis on optimizing stroke rehabilitation.Frontiers in neurology · 2025Pooled it
- Intelligent Sensing Technologies for the Diagnosis, Monitoring and Therapy of Alzheimer's Disease: A Systematic Review.Sensors (Basel, Switzerland) · 2021Pooled it
- PCA-Enhanced Deep Features for Alzheimer's Disease Stage Classification with EFMM.Diagnostics (Basel, Switzerland) · 2026Article
- Integrating acoustic, prosodic, and phonological features for automatic Alzheimer's detection.Frontiers in aging neuroscience · 2026Article
- A reagent-free, fouling-resistant electrochemical multifunctional peptide sensor for highly sensitive and rapid detection of Alzheimer's disease biomarkers.Materials today. Bio · 2025Article
- Remote Digital Technologies for the Early Detection and Monitoring of Cognitive Decline in Patients With Type 2 Diabetes: Insights From Studies of Neurodegenerative Diseases.Journal of diabetes science and technology · 2024Review
- Exercise Barriers in Older Individuals with Alzheimer's Disease: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2024Article
- A Framework for Interpretability in Machine Learning for Medical Imaging.IEEE access : practical innovations, open solutions · 2024Article
- Neurologists' approaches and challenges in managing early-stage Alzheimer's disease: A survey of clinical practices.Bioinformation · 2024Article
- Diagnostic accuracy study of automated stratification of Alzheimer's disease and mild cognitive impairment via deep learning based on MRI.Annals of translational medicine · 2022Article
- Does Dementia Have a Microbial Cause?NeuroSci · 2022Review
- Biosensors toward behavior detection in diagnosis of alzheimer's disease.Frontiers in bioengineering and biotechnology · 2022Review
- Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive Decline From Clinical Notes in Electronic Health Records.JAMA network open · 2021Article
- Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer's Disease.International journal of molecular sciences · 2021Review
- DailyCog: A Real-World Functional Cognitive Mobile Application for Evaluating Mild Cognitive Impairment (MCI) in Parkinson's Disease.Sensors (Basel, Switzerland) · 2021Article
- Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer's Clinical Notes.Geriatrics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Dementia is a syndrome that is characterised by the decline of different cognitive abilities. A high rate of deaths and high cost for detection, treatments, and patients care count amongst its consequences. Although there is no cure for dementia, a timely diagnosis helps in obtaining necessary support, appropriate medication, and maintenance, as far as possible, of engagement in intellectual, social, and physical activities. The early detection of Alzheimer Disease (AD) is considered to be of high importance for improving the quality of life of patients and their families. In particular, Virtual Reality (VR) is an expanding tool that can be used in order to assess cognitive abilities while navigating through a Virtual Environment (VE). The paper summarises common AD screening and diagnosis techniques focusing on the latest approaches that are based on Virtual Environments, behaviour analysis, and emotions recognition, aiming to provide more reliable and non-invasive diagnostics at home or in a clinical environment. Furthermore, different AD diagnosis evaluation methods and metrics are presented and discussed together with an overview of the different datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.